skip links

Media Inquiries

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]
Sort by Year
November 22, 2022

Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 3, 2022

Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

October 20, 2022

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

September 6, 2022

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

September 1, 2022

Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

August 4, 2022

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

July 21, 2022

Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

May 25, 2022

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

May 9, 2022

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

May 5, 2022

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

April 21, 2022

Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call

March 2, 2022

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

February 17, 2022

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021

February 3, 2022

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call

January 10, 2022

Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance